Muscle Spasticity Market
- 2026 年市場規模
- USD 11.4 Bn
- 2033 年預估規模
- USD 23.7 Bn
- 年複合成長率 CAGR
- 8.9%
以上數字由 Coherent Market Insights 於本報告中提出，量子訊息原樣引用。
授權報價
| Single User Price | $4,500 USD |
| Enterprise License | $10,000 USD |
完整報告名稱與涵蓋範圍
Muscle Spasticity Market, By Drug Type (Baclofen, Botulinum Toxin, Diazepam, Tizanidine, Dantrolene Sodium, and Others), By Route of Administration (Oral, Intramuscular, and Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East & Africa)
報告摘要
When muscles become stiff or contract, the condition is called as muscle spasticity. Muscle spasticity is seen in a variety of conditions such as spinal cord injury, brain injury, diseases such as amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS). It occurs when the nerve impulses involved in controlling muscle movement are either damaged or interrupted. Muscle spasticity can cause a difficulty in talking, moving, or stretching.
Symptoms of muscle spasticity include increased muscle tone, involuntary movements, abnormal posture, pain or discomfort, bone and joint deformities, decreased ability to function, and others. Spasticity should be treated when it causes pain, interferes with daily activities or sleep, or leads to decreased ability to function. Treatment given is based on the patient’s needs, preferences, and goals. The treatment includes physical therapy, occupational therapy, casting or bracing, and oral medications. Surgery may also be needed in certain cases. Oral medications are only used when the symptoms interfere with daily activities or sleep. Common medications include baclofen, dantrolene sodium, botulinum toxin, diazepam, and others.
Market Dynamics
The increasing launches of new drugs and regulatory approvals for muscle spasticity are expected to drive the market growth during the forecast period. For instance, in July 2021, Merz Therapeutics, a business of the Merz Group and a leader in the field of neurotoxins, and Teijin Pharma Limited, the core company of the Teijin Group’s healthcare business, jointly announced that Teijin Pharma was granted additional approval by Japan’s Ministry of Health, Labor and Welfare (MHLW) to market Xeomin (incobotulinumtoxinA), a neurotoxin treatment for intramuscular injection in 50, 100 or 200 units for the treatment of lower limb spasticity.
Key features of the study
• This report provides an in-depth analysis of the global muscle spasticity market, and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2026–2033), considering 2025 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global muscle spasticity market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include Ipsen Pharma, Allergan, Acorda Therapeutics, Inc., Merz Pharma, Teva Pharmaceutical Industries Ltd., Novartis AG, Sun Pharmaceutical Industries Ltd., Beximco Pharmaceuticals Ltd., Johnson & Johnson Private Limited, Zydus Cadila, F. Hoffmann-La Roche Ltd., and Elite Pharmaceuticals Inc.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• The global muscle spasticity market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global muscle spasticity market
Market Segmentation
• By Drug Type (Revenue, USD Bn, 2021-2033)
o Baclofen
o Botulinum Toxin
o Diazepam
o Tizanidine
o Dantrolene Sodium
o Others
• By Route of Administration (Revenue, USD Bn, 2021-2033)
o Oral
o Intramuscular
o Others
• By Distribution Channel (Revenue, USD Bn, 2021-2033)
o Hospital Pharmacies
o Retail Pharmacies
o Online Pharmacies
• By Region (Revenue, USD Bn, 2021-2033)
o North America
U.S.
Canada
o Latin America
Brazil
Mexico
Argentina
Rest of Latin America
o Europe
Germany
U.K.
France
Italy
Spain
Russia
Rest of Europe
o Asia Pacific
China
India
Japan
Australia
South Korea
ASEAN
Rest of Asia Pacific
o Middle East
GCC
Israel
Rest of Middle East
o Africa
South Africa
Central Africa
North Africa
• Key Players
o Ipsen Pharma
o Allergan
o Acorda Therapeutics, Inc.
o Merz Pharma
o Teva Pharmaceutical Industries Ltd.
o Novartis AG
o Sun Pharmaceutical Industries Ltd.
o Beximco Pharmaceuticals Ltd.
o Johnson & Johnson Private Limited
o Zydus Cadila
o Hoffmann-La Roche Ltd.
o Elite Pharmaceuticals Inc.
目錄 Table of Contents
Table of Contents
1. Research Objectives and Assumptions
o Research Objectives
o Assumptions
o Abbreviations
2. Market Purview
o Report Description
Market Definition and Scope
o Executive Summary
Market Snapshot, By Drug Type
Market Snapshot, By Route of Administration
Market Snapshot, By Distribution Channel
Market Snapshot, By Region
o Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
o Market Dynamics
Drivers
Restraints
Opportunity
o Impact Analysis
o Key Highlights
o Pipeline Analysis
o Regulatory Scenario
o Product Launches / Approvals
o PEST Analysis
o PORTER’s Analysis
o Merger, Collaboration and Acquisitions Scenario
4. Global Muscle Spasticity Market, By Drug Type, 2021-2033, (USD Bn)
o Introduction
Market Share Analysis, 2026 and 2033 (%)
Y-o-Y Growth Analysis, 2022-2033
Segment Trends
o Baclofen
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
o Botulinum Toxin
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
o Diazepam
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
o Tizanidine
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
o Dantrolene Sodium
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
o Others
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
5. Global Muscle Spasticity Market, By Route of Administration, 2021-2033, (USD Bn)
o Introduction
Market Share Analysis, 2026 and 2033 (%)
Y-o-Y Growth Analysis, 2022-2033
Segment Trends
o Oral
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
o Intramuscular
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
o Others
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
6. Global Muscle Spasticity Market, By Distribution Channel, 2021-2033, (USD Bn)
o Introduction
Market Share Analysis, 2026 and 2033 (%)
Y-o-Y Growth Analysis, 2022-2033
Segment Trends
o Hospital Pharmacies
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
o Retail Pharmacies
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
o Online Pharmacies
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
7. Global Muscle Spasticity Market, By Region, 2021-2033, (USD Bn)
o Introduction
Market Share Analysis, By Region, 2026 and 2033 (%)
Y-o-Y Growth Analysis, For Regions, 2022-2033
Regional Trends
o North America
Introduction
Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2021-2033, (USD Bn)
Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021-2033, (USD Bn)
Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021-2033, (USD Bn)
Market Size and Forecast, and Y-o-Y Growth, By Countries, 2021-2033, (USD Bn)
o U.S.
o Canada
o Latin America
Introduction
Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2021-2033, (USD Bn)
Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021-2033, (USD Bn)
Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021-2033, (USD Bn)
Market Size and Forecast, and Y-o-Y Growth, By Countries, 2021-2033, (USD Bn)
o Brazil
o Mexico
o Argentina
o Rest of Latin America
o Europe
Introduction
Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2021-2033, (USD Bn)
Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021-2033, (USD Bn)
Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021-2033, (USD Bn)
Market Size and Forecast, and Y-o-Y Growth, By Countries, 2021-2033, (USD Bn)
o U.K.
o Germany
o France
o Italy
o Spain
o Russia
o Rest of Europe
o Asia Pacific
Introduction
Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2021-2033, (USD Bn)
Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021-2033, (USD Bn)
Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021-2033, (USD Bn)
Market Size and Forecast, and Y-o-Y Growth, By Countries, 2021-2033, (USD Bn)
o China
o India
o Japan
o Australia
o South Korea
o ASEAN
o Rest of Asia Pacific
o Middle East
Introduction
Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2021-2033, (USD Bn)
Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021-2033, (USD Bn)
Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021-2033, (USD Bn)
Market Size and Forecast, and Y-o-Y Growth, By Countries, 2021-2033, (USD Bn)
o GCC
o Israel
o Rest of Middle East
o Africa
Introduction
Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2021-2033, (USD Bn)
Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021-2033, (USD Bn)
Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021-2033, (USD Bn)
Market Size and Forecast, and Y-o-Y Growth, By Region/Countries, 2021-2033, (USD Bn)
o North Africa
o Central Africa
o South Africa
8. Competitive Landscape
o Heat Map Analysis
o Market Share Analysis
Ipsen Pharma
o Company Highlights
o Product Portfolio
o Key Highlights
o Financial Performance
o Strategies
Allergan
o Company Highlights
o Product Portfolio
o Key Highlights
o Financial Performance
o Strategies
Acorda Therapeutics, Inc.
o Company Highlights
o Product Portfolio
o Key Highlights
o Financial Performance
o Strategies
Merz Pharma
o Company Highlights
o Product Portfolio
o Key Highlights
o Financial Performance
o Strategies
Teva Pharmaceutical Industries Ltd.
o Company Highlights
o Product Portfolio
o Key Highlights
o Financial Performance
o Strategies
Novartis AG
o Company Highlights
o Product Portfolio
o Key Highlights
o Financial Performance
o Strategies
Sun Pharmaceutical Industries Ltd.
o Company Highlights
o Product Portfolio
o Key Highlights
o Financial Performance
o Strategies
Beximco Pharmaceuticals Ltd.
o Company Highlights
o Product Portfolio
o Key Highlights
o Financial Performance
o Strategies
Johnson & Johnson Private Limited
o Company Highlights
o Product Portfolio
o Key Highlights
o Financial Performance
o Strategies
Zydus Cadila
o Company Highlights
o Product Portfolio
o Key Highlights
o Financial Performance
o Strategies
Hoffmann-La Roche Ltd
o Company Highlights
o Product Portfolio
o Key Highlights
o Financial Performance
o Strategies
Elite Pharmaceuticals Inc
o Company Highlights
o Product Portfolio
o Key Highlights
o Financial Performance
o Strategies
o Analyst Views
9. Section
o Research Methodology
o About us
提及公司
同分類最新報告（醫療與生命科學）
常見問題
這份報告可以先索取樣本嗎？
可以。建議購買前先申請樣本，提出申請後約 2 個工作天內提供，您可以先確認內容涵蓋範圍是否符合需求。
報告價格如何計算？
報告以美元標價，台幣報價依當日匯率換算並加計 5% 營業稅。不同授權版本（單人／多人／企業全站）價格不同，量子訊息會評估您的使用情境後提供最優惠報價。
下單後多久交付？如何付款？
一般 3–7 個工作天交付，實際依出版商狀況於下單前確認。收到報告確認無誤後開立台幣發票，30 天內電匯付款即可。
量子訊息有限公司為 Coherent Market Insights 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們